Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study

被引：0
|
作者：
Chen, H.
Wang, L.
Wu, Y.
Wu, Y.
Ma, S.
Sen, Y.
Zhen, H.
Mo, Y.
Zhang, C.
Wang, Q.
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
582P
引用
收藏
页码：S1697 / S1697
页数：1
相关论文
共 50 条
  • [1] High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
    Chen, Haiyang
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    Yang, Sen
    He, Zhen
    Mo, Yuqing
    Zhang, Cuicui
    Wang, Qiming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
  • [3] Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer
    Zhao, Q.
    Deng, L.
    Zhang, Y.
    Zhou, X.
    Li, Y.
    Yu, M.
    Zhou, L.
    Zou, B.
    Liu, Y.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases
    Yu, Xiaoqing
    Sheng, Jiamin
    Pan, Guoqiang
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (05) : 1121 - 1128
  • [5] Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
    Wu, Z.
    Zhang, Q.
    He, Z.
    Ke, L.
    He, T.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1655 - S1655
  • [6] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] A real-world study of Afatinib plus ramucirumab in treatment-naive, EGFR-mutated, non-small cell lung cancer
    Huang, Chun-Yao
    Huang, Hui-Li
    Lan, Chou-Chin
    Huang, Yi-Chih
    Wu, Yao-Kuang
    BMC CANCER, 2023, 23 (01)
  • [8] Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial
    Bortolot, Martina
    Huijs, Jarno W. J.
    Brandsma, Dieta
    Compter, Annette
    van Geel, Robin M. J. M.
    Hendriks, Lizza E. L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (01) : 7 - 13
  • [9] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
    Li, Huiying
    Yu, Tingting
    Huang, Mingmin
    Guo, Aibin
    Qian, Xiaoping
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
  • [10] Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer
    Chen, H.
    Lin, M.
    Jiang, J.
    Liu, M.
    Lai, Z.
    Luo, Y.
    Ye, H.
    Chen, H.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S55 - S55
12345